$800,000.00 in Sales Expected for Myomo, Inc. (NASDAQ:MYO) This Quarter

Brokerages predict that Myomo, Inc. (NASDAQ:MYO) will announce sales of $800,000.00 for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Myomo’s earnings, with estimates ranging from $750,000.00 to $840,000.00. Myomo posted sales of $890,000.00 during the same quarter last year, which suggests a negative year-over-year growth rate of 10.1%. The firm is expected to report its next quarterly earnings results on Thursday, March 5th.

According to Zacks, analysts expect that Myomo will report full-year sales of $3.12 million for the current financial year, with estimates ranging from $3.07 million to $3.16 million. For the next year, analysts anticipate that the business will post sales of $6.20 million, with estimates ranging from $6.00 million to $6.40 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Myomo.

Myomo (NASDAQ:MYO) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, meeting the consensus estimate of ($0.16). The business had revenue of $0.61 million during the quarter, compared to analysts’ expectations of $1.30 million.

Separately, Roth Capital lowered shares of Myomo from a “buy” rating to a “neutral” rating in a report on Wednesday, November 13th.

MYO remained flat at $$0.49 during midday trading on Thursday. The company’s stock had a trading volume of 30,747 shares, compared to its average volume of 130,863. The business has a fifty day moving average of $0.57 and a 200 day moving average of $0.72. Myomo has a 12 month low of $0.43 and a 12 month high of $1.87.

About Myomo

Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.

Read More: How Do Mutual Funds Work?

Get a free copy of the Zacks research report on Myomo (MYO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit